RightFit
RecruitingPhase not listed

Brain NAD in Alzheimer's Disease

Measurement of Brain NAD Levels in Alzheimer's Patients and Control Subjects by 1H-MRS

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
65 Years to 80 Years
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study compares brain levels of NAD, a substance in the body, in people ages 65 to 80 with and without Alzheimer's disease. Participants will have two brain scans using magnetic resonance spectroscopy (MRS) to measure NAD, eight months apart.

The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease. Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Are 65 to 80 years old.
  • Can come to the Florida Atlantic University Clinical Research Unit.
  • Can speak and walk.
  • If you have Alzheimer's disease, your doctor must have diagnosed it based on a clinical exam and a positive amyloid PET scan or an FDA-approved blood or spinal fluid test.

Who can't join

  • Are younger than 65 or older than 80.
  • Have severe dementia and would need medicine to make you calm or sleepy for an MRI scan.
  • Receive Leqembi or Kinsula, anti-amyloid treatments given through a vein.
  • Have a pacemaker or other device or metal part in your body that is not safe for MRI.
  • Have ever had seizures.
  • Work at night.
  • Have cancer now or were diagnosed within the past 5 years, except surface-level squamous cell or basal cell skin cancer.
  • If you do not have Alzheimer's disease, score below 26 on the MoCA test of memory and thinking.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory. * Age 65 to 80 included. * People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test. Exclusion Criteria: * Under the age of 65 or over the age of 80. * Advanced dementia such that the person would require sedation for undergoing an MRI scan. * Receiving anti-amyloid intravenous treatments Leqembi or Kinsula. * Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part). * Having a history of seizures. * Working at night. * Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer). * People with no AD: MoCA test result lower than 26.

Study sites (1)

FL